CL2023002746A1 - Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas - Google Patents

Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas

Info

Publication number
CL2023002746A1
CL2023002746A1 CL2023002746A CL2023002746A CL2023002746A1 CL 2023002746 A1 CL2023002746 A1 CL 2023002746A1 CL 2023002746 A CL2023002746 A CL 2023002746A CL 2023002746 A CL2023002746 A CL 2023002746A CL 2023002746 A1 CL2023002746 A1 CL 2023002746A1
Authority
CL
Chile
Prior art keywords
line
inhibitors
systemic diseases
treat cns
cns
Prior art date
Application number
CL2023002746A
Other languages
English (en)
Inventor
Weber Eckard
G Cordingley Michael
Original Assignee
Transposon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposon Therapeutics Inc filed Critical Transposon Therapeutics Inc
Publication of CL2023002746A1 publication Critical patent/CL2023002746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona métodos para tratar o prevenir una enfermedad del SNC o sistémica en un sujeto que lo necesite, que comprenden administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor de LINE-1, o una composición farmacéutica del mismo.
CL2023002746A 2021-03-15 2023-09-14 Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas CL2023002746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163161050P 2021-03-15 2021-03-15

Publications (1)

Publication Number Publication Date
CL2023002746A1 true CL2023002746A1 (es) 2024-04-05

Family

ID=83321069

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002746A CL2023002746A1 (es) 2021-03-15 2023-09-14 Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas

Country Status (14)

Country Link
US (1) US20240173346A1 (es)
EP (1) EP4308237A1 (es)
JP (1) JP2024511973A (es)
KR (1) KR20230157430A (es)
CN (1) CN117355312A (es)
AU (1) AU2022237405A1 (es)
BR (1) BR112023018714A2 (es)
CA (1) CA3211369A1 (es)
CL (1) CL2023002746A1 (es)
DO (1) DOP2023000192A (es)
IL (1) IL305869A (es)
MA (1) MA62910A1 (es)
MX (1) MX2023010657A (es)
WO (1) WO2022197689A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164472A1 (en) * 2022-02-22 2023-08-31 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
WO2023192491A2 (en) * 2022-03-30 2023-10-05 Transposon Therapeutics, Inc. Nucleoside line-1 inhibitors
WO2024129788A1 (en) * 2022-12-13 2024-06-20 Brown University Small molecule inhibitors of the line-1 endonuclease domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907503A1 (en) * 2003-04-10 2015-08-19 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
EP2965760A1 (en) * 2014-07-09 2016-01-13 Université de Montpellier Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases
CN105012305A (zh) * 2015-07-24 2015-11-04 福建广生堂药业股份有限公司 拉米夫定及其药用盐治疗老年性黄斑部病变的用途
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
EP3914604A4 (en) * 2019-01-25 2022-10-19 Brown University COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING INFLAMMATION AND AGE-RELATED DISORDERS
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑

Also Published As

Publication number Publication date
IL305869A (en) 2023-11-01
MX2023010657A (es) 2023-09-21
EP4308237A1 (en) 2024-01-24
KR20230157430A (ko) 2023-11-16
AU2022237405A1 (en) 2023-11-02
CN117355312A (zh) 2024-01-05
US20240173346A1 (en) 2024-05-30
DOP2023000192A (es) 2024-02-29
CA3211369A1 (en) 2022-09-22
MA62910A1 (fr) 2023-12-29
JP2024511973A (ja) 2024-03-18
BR112023018714A2 (pt) 2023-10-24
WO2022197689A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
CL2020003330A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR119158A1 (es) Tratamientos de angioedema hereditario
CL2021002966A1 (es) Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
CL2023001952A1 (es) Inhibidores de alk2 para el tratamiento de la anemia (divisional).
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2022000214A1 (es) Inhibidores de enzimas
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
CL2021002217A1 (es) Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
WO2023192491A3 (en) Nucleoside line-1 inhibitors
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
AR115722A1 (es) Método para prevenir o tratar neuropatías periféricas o dolores asociados con enfermedades que tienen neuropatías periféricas o daños astrocíticos
AR069144A1 (es) Inhibidores del complemento c1q para la prevencion y el tratamiento del glaucoma
WO2023019095A3 (en) Momelotinib combination therapy
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.